Introduction {#sec1-1}
============

Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related deaths worldwide (McLean and El-Omar, 2014). The incidence of GC in young patients declined from 6.34% of all patients with GC 20 years ago to 4.49% in the most recent decade (Kitamura et al., 1996). The overall incidence of early-onset GC in Korea is estimated to be 3.55% (Korea Central Cancer Registry, 2014). The incidence of advanced GC in young patients is higher than that in the general patient population (Lee et al., 2016). As GC is usually detected at an advanced stage, improved surveillance and chemotherapy strategies are needed (Lee et al., 2016).

It is postulated that genetic factors may be more important in young patients with early-onset GC than in older patients with GC as the patients with early-onset GC are less exposed to environmental carcinogens (Correa and Shiao, 1994). The different clinicopathological profiles of early-onset GC compared to those of conventional gastric carcinomas suggest that early-onset GC represents a separate entity within gastric carcinogenesis (Milne et al., 2007). It is known that microsatellite instability, which usually occurs at a frequency of 15% in older patients with gastric carcinomas, is consistently absent in young patients (Hayden et al., 1997; Lim et al., 2003; Carvalho and Kanaar, 2014). Approximately 10% of young GC patients have a positive family history (Kokkola and Sipponen, 2001).

Regarding familial GC, truly hereditary cases are thought to account for 1--3% of global GC cases and includes at least three main syndromes: hereditary diffuse GC (HDGC), gastric adenocarcinoma and proximal polyposis of the stomach, and familial intestinal GC. A genetic basis has been found in only around 40% of families affected by HDGC (Oliveira et al., 2015). In early-onset GC, alterations in E-cadherin-mediated adhesion proteins are common whereas microsatellite instability is not (Hayden et al., 1997; Lim et al., 2003). Recently, germline mutations in *PALB2*, *BRCA1*, and *RAD51C* have been identified in patients with *HDGC*, indicating that defects in homologous recombination (HR) increase the GC risk (Sahasrabudhe et al., 2017). However, specific susceptibility genes in early-onset or familial GC have not been identified.

The DNA damage response (DDR) is a collective term for the plethora of intra- and intercellular signaling events and enzyme activities that result from the induction and cellular detection of DNA damage. These include events that lead to cell-cycle arrest, regulation of DNA replication, and repair or bypass of DNA damage (O'Connor, 2015).

Tumor cells harboring mutations in genes involved in HR, such as *BRCA1*, *BRCA2*, and *MRE11*, are particularly vulnerable to DNA damage (Vilar et al., 2011). A deficiency in DNA damage repair is a fundamental etiological factor in various human cancers. Germline mutations in a single copy of either *BRCA1* or *BRCA2* can cause hereditary breast and ovarian cancer syndrome, characterized by early-onset breast cancer, as well as increased risks of ovarian, pancreatic, stomach, laryngeal, fallopian tube, and prostate cancer. *BRCA1* and *BRCA2* expression patterns and their prognostic significance in digestive system cancers have been described to be associated with more advanced tumor stage (Wang et al., 2018).

*RAD51C* is a paralog of *RAD51*, with an important role in the DDR (Min et al., 2013). *RAD51C*-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib (Min et al., 2013). In non-small cell lung cancer, increased expression of *RAD51C* has been suggested to confer resistance to chemotherapy and/or radiotherapy (Chen et al., 2016).

Meiotic recombination 11 (MRE11), DNA repair protein Rad50 (RAD50), and Nijmegen breakage syndrome 1 (NBS1) form the MRN complex, which is required for the maintenance of genomic instability (Carvalho and Kanaar, 2014). This complex, in combination with ataxia telangiectasia mutated (ATM), coordinates the cellular detection and repair of DNA double-strand breaks (DSBs) (Altan et al., 2016). High expression of MRE11--RAD50--NBS1 is associated with poor prognosis and chemoresistance in GC (Altan et al., 2016) as well as poor response to neoadjuvant radiotherapy and prognosis in rectal cancer (Ho et al., 2018). The MRN complex is frequently not detected in low-grade epithelial ovarian cancer, suggesting high sensitivity to the PARP inhibitor (Brandt et al., 2017).

The formation of γH2AX foci is commonly used to quantitatively analyze DSB induction and repair. Analyses of γH2AX revealed deficiencies in nonhomologous end-joining, the dominant DSB repair pathway in mammalian cells (Rogakou, 1998; Rothkamm, 2003). Phosphorylated H2AX, designated as γH2AX, is visualized by immunofluorescence microscopy as discrete nuclear foci, reflecting sites of DSBs. γH2AX is significantly associated with a shorter survival in patients with gastric carcinoma (Hussein et al., 2018).

We compared the immunohistochemical profiles of four DDR markers and one pharmacodynamic biomarker, γH2AX, between early-onset or familial GC and sporadic GC tissues.

Materials and Methods {#sec1-2}
=====================

Patients {#sec2-1}
--------

Early-onset GC is defined as GC diagnosed before age 40 (Lai et al., 2008; Takatsu et al., 2016). Patients were selected from January 1993 to December 1999 at Seoul National University Hospital. Of 4123 patients who underwent gastrectomy for GC, 54 patients were 40 years old or younger. To determine clinical outcomes, each patient was followed up from the date of surgery. The mean follow-up time was 42 months (range 1--60 months). The 59 familial cases included in this study were individuals who had GC with at least two first-degree relatives with GC, including at least one patient diagnosed before the age of 50 years. As a sporadic GC cohort, the files of 337 patients with surgically resected primary gastric carcinoma of 40 years or older examined at the Department of Pathology, Seoul National University Hospital in 2004 were analyzed. This study was approved by the Institutional Review Board/Independent Ethics Committee of Seoul National University Hospital (H-1010-065-336).

Tissue arrays and immunohistochemistry (IHC) {#sec2-2}
--------------------------------------------

Four-micrometer tissue microarray sections were subjected to immunohistochemical staining by the standard streptavidin-biotin complex method. Sectioning was performed after the specimens were de-paraffinized and rinsed in phosphate-buffered saline. Antigen retrieval was performed using rehydrated sections. The primary antibodies used were as follows: anti-*BRCA1* (MS110; mouse monoclonal; 1:200; Abcam, Cambridge, UK), anti-BRCA2 (MAB2476; mouse monoclonal; 1:500; R&D Systems, Inc. Minneapolis, MN, USA), anti-Mre11 (ab214; mouse monoclonal; 1:100; Abcam, Cambridge, UK), anti-RAD51C (NBP1-19647; rabbit polyclonal; 1 : 300; Novus biologicals, Littleton CO, USA), and anti-phospho-Histone H2A.X (Ser139) (clone JBW300; mouse monoclonal; 1 : 300; Upstate, NY, USA).

Immunohistochemical assessment {#sec2-3}
------------------------------

Immunohistochemical results for *BRCA1*, *BRCA2*, *MRE11*, and *RAD51C* were scored according to nuclear staining. If fewer than 10% of nuclei were positive, the result was considered negative. Otherwise, the result was considered positive (Kim et al., 2013). Immunohistochemical staining was performed to detect nuclear γH2AX. The staining intensity was scored on a scale of zero to three (0, no staining; 1, weak staining; 2, intermediate staining; 3, strong staining). The staining area was scored on a scale of zero to five (0, no stained cells; 1, 1% of the cells were positive; 2, 2--10% of the cells were positive; 3, 11--33% of the cells were positive; 4, 34--66% of the cells were positive; 5, 67--100% of the cells were positive). The sum of the scores ranged from zero to eight. Subsequently, the summed scores for the nuclear expression of γH2AX were grouped as positive or negative in the receiver operating characteristic curve analysis using the highest positive likelihood ratio for the prediction of GC-related death (Park et al., 2015; Hussein et al., 2018).

Statistical analysis {#sec2-4}
--------------------

Statistical analyses were performed using SPSS 17.0. Univariate and multivariate analyses were performed by chi-squared and Log-rank tests. Kaplan and Meier (1958) plots were used to visualize the survival distribution of patient subgroups, with differences in survival estimated using Log-rank tests. A value of p \< 0.05 (two-tailed) was considered significant.

Results {#sec1-3}
=======

DNA damage response (DDR) -related protein expression {#sec2-5}
-----------------------------------------------------

The expression levels of *BRCA1*, *BRCA2*, *MRE11*, *RAD51C*, and *γH2AX* were determined by IHC. Representative results of IHC staining are shown in [Figure 1](#F1){ref-type="fig"}. For comparative analysis of the IHC results, we grouped the samples into early-onset, familial, early-onset or familial, and sporadic GC according to previously established criteria (Lai et al., 2008; Oliveira et al., 2015; Takatsu et al., 2016).

![Immunohistochemical Analysis of DNA Damage Response Proteins in Gastric Cancer Tissues. A, BRCA1 negative; B, BRCA1 positive; C, BRCA2 negative; D, BRCA2 positive; E, MRE11 negative; F, MRE11 positive; G, RAD51C negative; H, RAD51C positive; I, γH2AX negative; D, γH2AX positive (x200).](APJCP-20-1369-g001){#F1}

Comparison of clinicopathological and IHC parameters in early-onset or familial and sporadic GCs {#sec2-6}
------------------------------------------------------------------------------------------------

Histological parameters were compared among sporadic, early-onset, and familial GC, as summarized in [Table 1](#T1){ref-type="table"}. The ratio of males to females was significantly higher for sporadic GC than for early-onset or familial GC (p\<0.001). Significantly more early-onset and familial tumors were poorly differentiated than sporadic cancers (p \< 0.001); 85.4% of early-onset and familial tumors were poorly differentiated compared with 49.9% of the sporadic cancers. Similarly, diffuse type early-onset and familial tumors were significantly more frequent than diffuse type sporadic cancers (p \< 0.001); 80.9% of early-onset cancers were poorly differentiated compared with 37.1% of the sporadic cancers. Higher T stage, presence of lymph node metastasis, and higher TNM stage were significantly associated with early-onset or familial cancers (p\<0.001, p=0.002, and p\<0.001, respectively).

###### 

Patient Profiles and DNA Damage Response Protein Expression Results for Early-Onset or Familial Gastric Cancers and Sporadic Gastric Cancers

                                                    Early-onset   Familial    Early-onset or familial   Sporadic     Early-onset vs. sporadic   Familial vs. sporadic   Early-onset vs. familial   Early-onset or familial vs. sporadic
  --------------------------- --------------------- ------------- ----------- ------------------------- ------------ -------------------------- ----------------------- -------------------------- --------------------------------------
  Gender                      Male                  23 (42.6)     38 (64.4)   61 (54)                   251 (74.5)   \< 0.001                   0.108                   0.02                       \< 0.001
  Female                      31 (57.4)             21 (35.6)     52 (46)     86 (25.5)                                                                                                            
  Differentiation             Well-differentiated   0 (0)         2 (4.3)     2 (2.2)                   32 (9.5)     \< 0.001                   0.001                   not available              \< 0.001
  Moderately differentiated   3 (7)                 8 (17.4)      11 (12.4)   137 (40.7)                                                                                                           
  Poorly differentiated       40 (93)               36 (78.3)     76 (85.4)   168 (49.9)                                                                                                           
  Lauren classification       Intestinal            3 (7)         10 (21.7)   13 (14.6)                 156 (46.3)   \< 0.001                   \< 0.001                not available              \< 0.001
  Diffuse                     37 (86)               35 (76.1)     72 (80.9)   125 (37.1)                                                                                                           
  Mixed                       3 (7)                 1 (2.2)       4 (4.5)     56 (16.6)                                                                                                            
  T stage                     T1                    6 (14.3)      17 (35.4)   23 (25.6)                 115 (34.1)   \< 0.001                   \< 0.001                not available              \< 0.001
  T2                          3 (7.1)               5 (10.4)      8 (8.9)     179 (53.1)                                                                                                           
  T3                          18 (42.9)             14 (29.2)     32 (35.6)   41 (12.2)                                                                                                            
  T4                          15 (35.7)             12 (25)       27 (30)     2 (0.6)                                                                                                              
  LN metastasis               Absent                17 (39.5)     14 (28.6)   31 (33.7)                 176 (52.2)   0.117                      0.002                   0.267                      0.002
  Present                     26 (60.5)             35 (71.4)     61 (66.3)   161 (47.8)                                                                                                           
  TNM stage                   I                     9 (16.7)      17 (35.4)   26 (25.5)                 185 (54.9)   \< 0.001                   0.009                   0.03                       \< 0.001
  II                          21 (38.9)             20 (41.7)     41 (40.2)   75 (22.3)                                                                                                            
  III                         24 (44.4)             11 (22.9)     35 (34.3)   77 (22.8)                                                                                                            
  BRCA1                       Negative              24 (49)       22 (38.6)   46 (43.4)                 103 (36.5)   0.098                      0.767                   0.282                      0.215
  Positive                    25 (51)               35 (61.4)     60 (56.6)   179 (63.5)                                                                                                           
  BRCA2                       Negative              21 (47.7)     15 (26.3)   36 (35.6)                 128 (39.4)   0.29                       0.06                    0.026                      0.5
  Positive                    23 (52.3)             42 (73.7)     65 (64.4)   197 (60.6)                                                                                                           
  MRE11                       Negative              16 (33.3)     2 (3.5)     18 (17.1)                 117 (35.2)   0.796                      \< 0.001                \< 0.001                   \< 0.001
  Positive                    32 (66.7)             55 (96.5)     87 (82.9)   215 (64.8)                                                                                                           
  Rad51C                      Negative              7 (14.3)      9 (15.8)    16 (15.1)                 148 (46)     \< 0.001                   \< 0.001                0.829                      \< 0.001
  Positive                    42 (85.7)             48 (84.2)     90 (84.9)   174 (54)                                                                                                             
  H2AX                        Negative              16 (32)       12 (21.1)   28 (26.2)                 182 (64.1)   \< 0.001                   \< 0.001                0.199                      \< 0.001
  Positive                    34 (68)               45 (78.9)     79 (73.8)   102 (35.9)                                                                                                           

There were no significant differences in *BRCA1* and *BRCA2* protein expression between early-onset or familial GC and sporadic GC cases. In a comparison of DDR-related protein expression frequencies among the GC cohorts, *RAD51C* positivity was significantly higher in early-onset or familial GC (84.9%) than in sporadic GC (54.0%) (p \< 0.001). *γH2AX* was more frequently positive in early-onset or familial GC (73.8%) than in sporadic GC (35.9%) (p\<0.001) ([Table 1](#T1){ref-type="table"}).

Expression of DDR markers in early-onset or familial GC and sporadic GC {#sec2-7}
-----------------------------------------------------------------------

Clinicopathological features were not correlated with *BRCA1*, *BRCA2*, *MRE11*, and *γH2AX* expression. *RAD51C* expression was significantly associated with the presence of lymph node metastasis (p = 0.032) and higher TNM stage (p = 0.044) in early-onset or familial GC ([Table 2](#T2){ref-type="table"}).

###### 

Correlations between Clinicopathological Features and DNA Damage Response Proteins in Early-Onset or Familial Gastric Cancer

                                                    BRCA1       BRCA2       MRE11       Rad51C      γH2AX                                                                                                                  
  --------------------------- --------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- ----------- ----------- ----------- -------
  Gender                      Male                  22 (47.8)   33 (55)     0.464       14 (38.9)   38 (58.5)   0.059       12 (66.7)   43 (49.4)   0.182      8 (50)      47 (52.2)   0.87        17 (60.7)   39 (49.4)   0.302
  Female                      24 (52.2)             27 (45)                 22 (61.1)   27 (41.5)               6 (33.3)    44 (50.6)               8 (50)     43 (47.8)               11 (39.3)   40 (50.6)               
  Differentiation             Well differentiated   0 (0)       2 (4.2)     0.462       1 (3.3)     1 (2.1)     0.195       1 (8.3)     1 (1.4)     0.336      0 (0)       2 (2.9)     0.272       0 (0)       2 (3.2)     0.672
  Moderately differentiated   4 (11.4)              6 (12.5)                1 (3.3)     8 (16.7)                1 (8.3)     9 (12.9)                0 (0)      10 (14.3)               3 (14.3)    7 (11.3)                
  Poorly differentiated       31 (88.6)             40 (83.3)               28 (93.3)   39 (81.3)               10 (83.3)   60 (85.7)               13 (100)   58 (82.9)               18 (85.7)   53 (85.5)               
  Lauren classification       Intestinal            4 (11.4)    8 (16.7)    0.34        2 (6.7)     9 (18.8)    0.255       2 (16.7)    10 (14.3)   0.691      0 (0)       12 (17.1)   0.159       3 (14.3)    9 (14.5)    1
  Diffuse                     28 (80)               39 (81.3)               27 (90)     36 (75)                 10 (83.3)   56 (80)                 13 (100)   54 (77.1)               17 (81)     50 (80.6)               
  Mixed                       3 (8.6)               1 (2.1)                 1 (3.3)     3 (6.3)                 0 (0)       4 (5.7)                 0 (0)      4 (5.7)                 1 (4.8)     3 (4.8)                 
  T stage                     T1                    8 (22.2)    13 (26.5)   0.891       8 (26.7)    11 (22)     0.833       1 (7.7)     20 (28.2)   0.115      6 (46.2)    15 (20.8)   0.083       2 (9.1)     19 (30.2)   0.154
  T2                          2 (5.6)               4 (8.2)                 1 (3.3)     4 (8)                   0 (0)       6 (8.5)                 2 (15.4)   4 (5.6)                 2 (9.1)     4 (6.3)                 
  T3                          15 (41.7)             17 (34.7)               12 (40)     19 (38)                 5 (38.5)    27 (38)                 2 (15.4)   30 (41.7)               8 (36.4)    24 (38.1)               
  T4                          11 (30.6)             15 (30.6)               9 (30)      16 (32)                 7 (53.8)    18 (25.4)               3 (23.1)   23 (31.9)               10 (45.5)   16 (25.4)               
  LN metastasis               Absent                13 (35.1)   15 (30.6)   0.658       13 (41.9)   13 (26)     0.135       4 (30.8)    24 (33.3)   0.856      8 (57.1)    20 (27.8)   0.032       7 (31.8)    21 (32.8)   0.932
  Present                     24 (64.9)             34 (69.4)               18 (58.1)   37 (74)                 9 (69.2)    48 (66.7)               6 (42.9)   52 (72.2)               15 (68.2)   43 (67.2)               
  TNM stage                   I                     8 (19.5)    15 (27.8)   0.561       8 (23.5)    12 (21.4)   0.945       1 (5.6)     22 (28.9)   0.015      7 (50)      16 (19.8)   0.044       2 (7.7)     21 (30)     0.062
  II                          19 (46.3)             20 (37)                 14 (41.2)   25 (44.6)               6 (33.3)    33 (43.4)               3 (21.4)   36 (44.4)               14 (53.8)   25 (35.7)               
  III                         14 (34.1)             19 (35.2)               12 (35.3)   19 (33.9)               11 (61.1)   21 (27.6)               4 (28.6)   29 (35.8)               10 (38.5)   24 (34.3)               

In contrast, these DDR markers were significant correlated with clinicopathological variables in sporadic GC. Thus, *BRCA1* negativity correlated with poor differentiation (p = 0.016), advanced T stage (p = 0.001), and positive lymph node metastasis (p \< 0.001); BRCA2 negativity correlated with poor differentiation (p \< 0.001); and RAD51C negativity correlated with poor differentiation (p \< 0.001) ([Table 3](#T3){ref-type="table"}).

###### 

Correlations between Clinicopathological Features and DNA Damage Response proteins in Sporadic Gastric Cancer

                                                    BRCA1       BRCA2        MRE11       Rad51C       γH2AX                                                                                                                          
  --------------------------- --------------------- ----------- ------------ ----------- ------------ ------------ ----------- ------------ ------------ ----------- ------------ ------------ ------------ ------------ ----------- ----------
  Gender                      Male                  70 (68)     142 (79.3)   0.033       90 (70.3)    153 (77.7)   0.136       85 (72.6)    163 (75.8)   0.526       111 (75)     129 (74.1)   0.86         130 (71.4)   81 (79.4)   0.14
  Female                      33 (32)               37 (20.7)                38 (29.7)   44 (22.3)                 32 (27.4)   52 (24.2)                 37 (25)     45 (25.9)                 52 (28.6)    21 (20.6)                
  Differentiation             Well differentiated   2 (1.9)     28 (15.6)    \< 0.001    8 (6.3)      22 (11.2)    \< 0.001    7 (6)        24 (11.2)    0.116       13 (8.8)     18 (10.3)    \< 0.001     10 (5.5)     16 (15.7)   0.001
  Moderately differentiated   37 (35.9)             77 (43)                  39 (30.5)   97 (49.2)                 44 (37.6)   92 (42.8)                 43 (29.1)   88 (50.6)                 71 (39)      50 (49)                  
  Poorly differentiated       64 (62.1)             74 (41.3)                81 (63.3)   78 (39.6)                 66 (56.4)   99 (46)                   92 (62.2)   68 (39.1)                 101 (55.5)   36 (35.3)                
  Lauren classification       Intestinal            37 (35.9)   96 (53.6)    0.016       36 (28.1)    117 (59.4)   \< 0.001    52 (44.4)    102 (47.4)   0.734       44 (29.7)    104 (59.8)   \< 0.001     77 (42.3)    56 (54.9)   0.008
  Diffuse                     46 (44.7)             56 (31.3)                66 (51.6)   52 (26.4)                 47 (40.2)   77 (35.8)                 74 (50)     45 (25.9)                 78 (42.9)    25 (24.5)                
  Mixed                       20 (19.4)             27 (15.1)                26 (20.3)   28 (14.2)                 18 (15.4)   36 (16.7)                 30 (20.3)   25 (14.4)                 27 (14.8)    21 (20.6)                
  T stage                     T1                    20 (19.4)   72 (40.2)    0.001       58 (45.3)    52 (26.4)    0.003       26 (22.2)    87 (40.5)    0.003       60 (40.5)    48 (27.6)    0.008        40 (22)      47 (46.1)   \< 0.001
  T2                          64 (62.1)             89 (49.7)                55 (43)     119 (60.4)                78 (66.7)   100 (46.5)                65 (43.9)   106 (60.9)                109 (59.9)   49 (48)                  
  T3                          19 (18.4)             16 (8.9)                 15 (11.7)   24 (12.2)                 13 (11.1)   26 (12.1)                 23 (15.5)   18 (10.3)                 33 (18.1)    4 (3.9)                  
  T4                          0 (0)                 2 (1.1)                  0 (0)       2 (1)                     0 (0)       2 (0.9)                   0 (0)       2 (1.1)                   0 (0)        2 (2)                    
  LN metastasis               Absent                39 (37.9)   102 (57)     0.002       75 (58.6)    92 (46.7)    0.036       50 (42.7)    123 (57.2)   0.012       78 (52.7)    89 (51.1)    0.781        77 (42.3)    64 (62.7)   0.001
  Present                     64 (62.1)             77 (43)                  53 (41.4)   105 (53.3)                67 (57.3)   92 (42.8)                 70 (47.3)   85 (48.9)                 105 (57.7)   38 (37.3)                
  TNM stage                   I                     42 (40.8)   108 (60.3)   0.002       80 (62.5)    97 (49.2)    0.062       54 (46.2)    128 (59.5)   0.064       84 (56.8)    92 (52.9)    0.526        81 (44.5)    67 (65.7)   0
  II                          23 (22.3)             37 (20.7)                24 (18.8)   48 (24.4)                 32 (27.4)   43 (20)                   28 (18.9)   42 (24.1)                 40 (22)      24 (23.5)                
  III                         38 (36.9)             34 (19)                  24 (18.8)   52 (26.4)                 31 (26.5)   44 (20.5)                 36 (24.3)   40 (23)                   61 (33.5)    11 (10.8)                

Early-onset or familial cancer and patient outcomes {#sec2-8}
---------------------------------------------------

A Kaplan--Meier analysis of overall survival showed slightly higher survival rates for sporadic GC than for early-onset or familial GC, but the difference was not significant. In a univariate survival analysis according to DDR expression, *BRCA1* negativity was associated with a decreased overall survival only in sporadic GC (p = 0.002), and MRE11 negativity was associated with a decreased overall survival only in sporadic GC (p = 0.012) ([Figure 2](#F2){ref-type="fig"}).

![Kaplan--Meier Analyses of Overall Survival According to BRCA1 and MRE11 Expression in Early-Onset or Familial and Sporadic Gastric Cancers. A, BRCA1 in early-onset or familial gastric cancer; B, BRCA1 in sporadic gastric cancer; C, MRE11 in early-onset or familial gastric cancer; D, MRE11 in sporadic gastric cancer. Dotted line, negative expression of protein; solid line, positive expression of protein](APJCP-20-1369-g002){#F2}

Multivariate analyses showed that the DDR is not correlated with survival in early-onset or familial and sporadic GC (data not shown).

Discussion {#sec1-4}
==========

GC is classified into sporadic and familial forms; although most GC cases are sporadic, aggregation within families accounts for roughly 10% of cases. Mutations in CDH1 and CTNNA1 are associated with familial GC risk (Oliveira et al., 2015). Molecular expression profiles of early-onset GC and conventional GC have been found to differ. Early-onset GC less frequently expresses cyclooxygenase-2 (COX-2) and Trefoil Factor-1 (TFF-1) (Milne et al., 2006) and more frequently aberrantly expresses E-Cadherin regardless of the histological type (Lim et al., 2003).

Our results showed that early-onset or familial GC is substantially more aggressive than sporadic GC. These results are concordant with those of previous studies reporting greater aggressiveness and lethality for early-onset GC compared to that in the general population (Smith and Stabile, 2009; Kong et al., 2012; Lee et al., 2016).

We detected differences in the expression profiles of RAD51C and γH2AX between early-onset or familial GC and sporadic GC. DDR has been implicated in tumorigenesis and progression in human cancers. The impairment of DDR causes genetic instability and may affect prognosis and susceptibility to chemotherapy in GC (Bartkova et al., 2005). In GC, elevated levels of γH2AX and pATM are adverse factors for progression-free and overall survival (Ronchetti et al., 2017). Additionally, the expression of the MRN complex is associated with a poor prognosis and negatively associated with the expression of the DNA damage marker *γH2AX* in the nucleus (Altan et al., 2016).

DSB repair is mediated by two principal mechanisms: non-homologous end-joining and HR (Jackson and Bartek, 2009). In mammals, the core of the HR pathway includes the MRE11-RAD50-NBS1 complex and RAD51 and RAD51 paralogs (Carvalho and Kanaar, 2014). HR-defective tumors are more sensitive to DNA-damaging agents, such as cisplatin and IR. Mutations in HR-associated genes, such as *BRCA1* and *BRCA2*, are responsible for approximately 40% of the genetic predisposition to familial breast and ovarian cancers (Somyajit et al., 2010). HR-defective tumors may be more sensitive to chemoradiotherapeutic strategies that promote DNA damage. PARP inhibitors targeting DDR pathways exhibit potent anticancer activity in preclinical models and clinical studies of GC, especially in those with low ATM or RAD51 expression (Kim et al., 2013). RAD51C-deficient cancer cells are highly sensitive to the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Min et al., 2013). RAD51C has been characterized as a cancer susceptibility gene (Somyajit et al., 2010). Biallelic mutations in RAD51C lead to Fanconi anemia-like disorder, and monoallelic mutations in RAD51C are associated with an increased risk of breast and ovarian cancer (Somyajit et al., 2010).

Our study is a retrospective clinical study using IHC and tissue microarray. Intratumoral heterogeneity has become an important issue in cancer therapeutics (Gerlinger et al., 2012). For clinical application of the DDR-related proteins identified in this study as tumor biomarkers, further investigation regarding intratumoral heterogeneity would be required.

Our results showed that early-onset or familial GC and sporadic GC have significantly different clinicopathologic characteristics and DDR marker expression patterns, especially with respect to RAD51C and γH2AX. In particular, early-onset or familial GC is significantly associated with RAD51C and γH2AX. The observation that early-onset or familial GC has higher rates of DDR deficiency could contribute to the prediction of the response to chemotherapy. These results suggest that early-onset or familial GC might have a higher degree of deregulation of DDR, raising the possibility that this form of GC has higher chemotherapy sensitivity than sporadic GC.
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